MIIP Polyclonal Antibody
Purified Rabbit Polyclonal Antibody (Pab)
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application ![]()
| IHC-P, IHC-F, IF, E |
---|---|
Primary Accession | Q5JXC2 |
Reactivity | Rat, Dog, Bovine |
Host | Rabbit |
Clonality | Polyclonal |
Calculated MW | 43 KDa |
Physical State | Liquid |
Immunogen | KLH conjugated synthetic peptide derived from human MIIP |
Epitope Specificity | 251-350/388 |
Isotype | IgG |
Purity | affinity purified by Protein A |
Buffer | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
SUBUNIT | Interacts with IGFBP2. |
Post-translational modifications | Isoform 2 is degraded by the ubiquitin-proteasome pathway. |
Important Note | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
Background Descriptions | MIIP has 3 SEG (segments of low compositional complexity) domains, an RGD motif, and several potential phosphorylation sites. The C-terminal region of IGFBP2 interacts with a central 44-amino acid sequence of MIIP. MIIP inhibits glioma cells invasion and down-regulates adhesion- and motility-associated genes such as NFKB2 and ICAM1. It exhibits opposing effects to IGFBP2 on cell invasion. There are 2 named isoforms due to alternative splicing. Isoform 1 is expressed in brain but underexpressed in glioma tissues, at protein level. Isoform 2 is not detected in normal organs, but is expressed in gliomas with increasing levels with glioma progression. On the contrary, at protein level, isoform 2 is not detected in gliomas, suggesting that this isoform is unstable in glioma cells. Isoform 2 is degraded by the ubiquitin-proteasome pathway. |
Gene ID | 60672 |
---|---|
Other Names | Migration and invasion-inhibitory protein, IGFBP2-binding protein, Invasion-inhibitory protein 45, IIp45, MIIP, IIP45 |
Target/Specificity | Ubiquitous. Isoform 1 is expressed in brain but underexpressed in glioma tissues, at protein level. Isoform 2 is not detected in normal organs, but is expressed in gliomas with increasing levels with glioma progression. On the contrary, at protein level, isoform 2 is not detected in gliomas, suggesting that this isoform is unstable in glioma cells. |
Dilution | IHC-P=1:100-500,IHC-F=1:100-500,IF=1:100-500,ELISA=1:5000-10000 |
Format | 0.01M TBS(pH7.4), 0.09% (W/V) sodium azide and 50% Glyce |
Storage | Store at -20 ℃ for one year. Avoid repeated freeze/thaw cycles. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 ℃. |
Name | MIIP |
---|---|
Synonyms | IIP45 |
Function | Inhibits glioma cells invasion and down-regulates adhesion- and motility-associated genes such as NFKB2 and ICAM1. Exhibits opposing effects to IGFBP2 on cell invasion. |
Tissue Location | Ubiquitous. Isoform 1 is expressed in brain but underexpressed in glioma tissues, at protein level. Isoform 2 is not detected in normal organs, but is expressed in gliomas with increasing levels with glioma progression. On the contrary, at protein level, isoform 2 is not detected in gliomas, suggesting that this isoform is unstable in glioma cells. |

Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.

If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.